尤瑞克林对急性脑梗死患者SDF-1、ET-1和VEGF及认知功能的影响  

The effect of urinary kallidinogenase on SDF-1,ET-1,VEGF,cognitive function in patients with acute cerebral infarction

作　　者：欧春影[1] 李传玲[1] 郭靖[1] 李晓宾[1] 安晓雷[1] 许可[1] Ou Chunying;Li Chuanling;Guo Jing;Li Xiaobin;An Xiaolei;Xu Ke(Department of Neurology,Xuzhou Central Hospital,Xuzhou 221000,China)

机构地区：[1]徐州市中心医院神经内科,江苏徐州221000

出　　处：《中华脑血管病杂志（电子版）》2020年第4期217-220,共4页Chinese Journal of Cerebrovascular Diseases(Electronic Edition)

基　　金：江苏省科技局基金(BL2014028)。

摘　　要：目的探讨尤瑞克林对急性脑梗死患者基质细胞衍生因子-1(SDF-1)、血管内皮素-1(ET-1)和血管内皮生长因子(VEGF)及认知功能的影响。方法选取徐州市中心医院2017年1月至2018年5月住院的急性脑梗死患者60例,随机分为对照组和治疗组各30例,对照组给予急性脑梗死患者常规神经内科药物治疗,治疗组在对照组基础上另外给予注射用尤瑞克林0.15 PNA,疗程14 d。分别于治疗前及治疗14 d行SDF-1、ET-1和VEGF浓度测定及蒙特利尔认知量表(MoCA)评分,观察3个月后再次进行MoCA评分。采用独立样本t检验比较血浆SDF-1、ET-1及VEGF浓度、MoCA评分的组间差异。结果2组患者在治疗前SDF-1、ET-1和VEGF浓度及MoCA评分比较,差异均无统计学意义(P均>0.05);治疗14 d后,治疗组ET-1浓度较对照组降低[(57.33±14.61)pg/L vs(65.17±12.88)pg/L],SDF-1、VEGF较对照组升高[(4024.10±379.30)pg/ml vs(3171.60±337.00)pg/ml;(316.38±84.27)ng/ml vs(250.26±93.56)ng/ml],差异均具有统计学意义(t=4.865,P=0.031;t=84.693,P<0.001;t=8.272,P=0.006);3个月后MoCA评分治疗组较对照组高[(26.60±1.75)分vs(25.07±3.60)分],差异具有统计学意义(t=4.417,P=0.040)。结论尤瑞克林较常规治疗降低急性脑梗死患者的ET-1浓度,促进SDF-1、VEGF的分泌,从而改善急性脑梗死患者的认知功能。Objective To investigate the effect of urinary kallidinogenase on stromal cell-derived factor-1(SDF-1),vascular endothelin-1(ET-1),vascular endothelial growth factor(VEGF)and cognitive function in patients with acute cerebral infarction.Methods Sixty patients with acute cerebral infarction hospitalized in Xuzhou Central Hospital from January 2017 to May 2018 were randomly enrolled in control group and treatment group,30 cases in each group.The control group received routine neurological medicine for acute cerebral infarction,and the treatment group received additional use of urinary kallidinogenase 0.15 PNA for injection.The course of treatment is 14 days.The concentration of SDF-1,ET-1,VEGF and MoCA score were measured before treatment and 14 days after treatment.The MoCA score was evaluated again 3 months after treatment.Results There were no significant differences in concentration of SDF-1,ET-1,VEGF,and MoCA scores between the two groups.After 14 days of treatment,the concentration of ET-1 in the treatment group[(57.33±14.61)pg/L]was significantly lower than that in the control group[(65.17±12.88)pg/L,P=0.031].SDF-1[(4024.10±379.30)pg/ml],VEGF[(316.38±84.27)ng/ml]in the treatment group were significantly higher than SDF-1[(3171.60±337.00)pg/ml,P<0.001],VEGF[(250.26±93.56)ng/ml,P=0.006]in the control group three months after treatment,the MoCA score(26.60±1.75)was significantly higher than the control group(25.07±3.60,P=0.040).Conclusion Urinary kallidinogenase reduced the concentration of ET-1 in patients with acute cerebral infarction and increased the level of SDF-1 and VEGF,and possibly improving the cognitive function of patients with acute cerebral infarction.

关 键 词：尤瑞克林 基质细胞衍生因子-1 内皮素-1 血管内皮生长因子 认知功能 

分 类 号：R743.3[医药卫生—神经病学与精神病学]